Market Intelligence Analysis of Polycaprolactone (PCL) Commercial Market

I. Recent Price Dynamics
- Price Level: As of April 30, 2026, the domestic standard-grade polycaprolactone (PCL) market price in China remains stable at RMB 53,000 per ton, unchanged from the level on January 16, 2026, and sustaining within the upper range of the past 12 months. In January 2026, the market price ranged between RMB 32,000–38,000 per ton—down from the historical oscillation band of RMB 35,000–45,000 per ton observed during 2023–2025—primarily driven by improved supply-demand balance and reduced raw material costs.
- Import Prices: Premium medical-grade PCL is quoted at RMB 8.00 per gram (approximately RMB 80,000 per ton), reflecting strong market demand for high-purity, customized products.

II. Supply-Demand Analysis
- Capacity Expansion: China’s PCL production capacity exceeded 50,000 tons/year in 2025. In 2026, over 40,000 tons/year of new capacity is planned, concentrated mainly in the East and South China regions; Southwest China is establishing a differentiated layout leveraging its green energy infrastructure. Hunan Jurun New Materials Co., Ltd. has completed construction of a 55,000-ton/year caprolactone-series products facility, positioning itself as one of the world’s largest producers.
- Raw Material Localization: The domestic localization rate of ε-caprolactone (CL) is projected to rise from under 30% in 2025 to over 50% in 2026. Companies including Wanhua Chemical and Hualu Hengsheng are accelerating CL project deployment, driving down PCL production costs by 15%–20%. As of late November 2025, cyclohexanone prices stood at RMB 6,575 per ton—a 27.88% year-on-year decline—further compressing PCL raw material costs.
- Demand Growth:
Medical Sector: The market size reached RMB 1.488 billion in 2024, growing 8.22% year-on-year and accounting for ~45% of total demand. Demand continues to rise for absorbable sutures, drug delivery carriers, and tissue engineering scaffolds, with increasing adoption of minimally invasive surgery boosting the share of premium products.
Eco-Friendly Packaging: Regulatory mandates phasing out conventional plastics have elevated the penetration rate of PCL-based composites in frozen food packaging and courier bags to over 20%. Effective December 2025, the Mandatory National Standard for Green Express Packaging stipulates that biodegradable materials must constitute no less than 35% of cold-chain packaging for fresh e-commerce logistics; PCL stands alone among biodegradable substrates in fully satisfying end-to-end temperature-controlled requirements due to its low-temperature toughness and high puncture resistance.
3D Printing: Demand for medical-grade PCL grows at ~30% annually; emerging applications—including flexible electronics and self-healing coatings—are gradually entering commercialization.
Import Dependence: Despite rapid domestic capacity expansion, high-end medical-grade PCL remains partially import-dependent, with a domestic substitution rate below 60%.

III. Key Market Drivers
- Policy Support: China’s “Dual Carbon” strategy and the “14th Five-Year Plan for Bioeconomic Development” explicitly endorse biodegradable materials such as PCL, with multiple provincial governments introducing dedicated subsidies and tax incentives.
- Technological Breakthroughs: Domestic breakthroughs in CL monomer production have significantly reduced reliance on Japanese and German suppliers, enhancing end-to-end controllability of the PCL value chain. Hunan Jurun New Materials operates the world’s largest single-line 50,000-ton/year caprolactone production facility, while Shenzhen Guanghua Weiyeh holds the globally unique continuous polymerization technology for PCL.
- Market Demand: Aging demographics and expanding minimally invasive surgical procedures fuel demand for high-end medical products; escalating plastic bans and heightened consumer environmental awareness drive growth in biodegradable packaging.

IV. Future Trend Outlook
- Price Trend: Stable pricing is supported by cost reductions and balanced supply-demand dynamics. While standard-grade PCL is expected to remain in the RMB 32,000–38,000/ton range, premium medical-grade products will retain pricing premiums due to stringent regulatory certification barriers.
- Supply-Demand Balance: Gradual commissioning of new capacity will narrow—but not eliminate—the supply gap, as high-end demand in healthcare and eco-packaging continues robust growth.
- Accelerated Import Substitution: Breakthroughs in domestic CL monomer production reduce foreign dependence and strengthen value chain autonomy; however, full substitution of high-end products will require additional time and clinical/commercial validation.
- Scale Expansion: The overall PCL market is projected to reach RMB 5.8 billion by 2030, growing at a compound annual growth rate (CAGR) exceeding 25%.
- Vertical Integration: Industry players are transitioning from standalone upstream raw material production toward integrated operations spanning CL monomer → PCL resin → downstream applications—enhancing profitability and supply chain resilience.
- Global Competition: Through technological innovation and scale expansion, domestic enterprises are progressively displacing international incumbents—including BASF and Covestro—in the Chinese market and advancing toward leadership in the global biodegradable materials supply chain.
- High-Performance Enhancement: Enzyme-catalyzed synthesis, nanocomposite modification, and other advanced technologies are propelling PCL into higher-value medical-grade and electronics-grade applications; molecular design and composite engineering have become core competitive differentiators.
- Green & Low-Carbon Transformation: PCL manufacturing processes are increasingly integrating green hydrogen and bio-based CL feedstocks to reduce carbon emissions, aligning with global net-zero objectives.